Rapid development of central adiposity after postexposure prophylaxis with antiretroviral drugs: A proof of principle? [9]

AIDS

Volumn 17, Issue 6, 2003, Pages 944-945

  Mauss, Stefan ^a   Berger, Florian ^a   Carls, Horst ^a   Schmutz, Guenther ^a  

^a Center for HIV and Hepatogastroenterology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; STAVUDINE;

ADULT; CASE REPORT; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LETTER; LIPOHYPERTROPHY; MALE; OBESITY; PRIORITY JOURNAL; SEXUAL BEHAVIOR;

ABDOMEN; ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; HYPERTROPHY; MALE;

EID: 0037625906     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304110-00032     Document Type: Letter

References (6)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy and insulin resistance due to HIV protease inhibitors. AIDS 1998, 12:F51-F58.
2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
3. Mallal S, John M, Moore C, James I, McKinnon E. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309-1316.
4. Martínez E, Mocroft A, García-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001, 357:592-598.
5. Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jäger H, et al. Risk factors fort the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002, 3:49-55.
6. Miller KD, Jones E, Jack A, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998, 351:871-875.